MEDIPHARM LABS CORP (LABS.CA) Stock Price & Overview
TSX:LABS • CA58504D1006
Current stock price
The current stock price of LABS.CA is 0.065 CAD. Today LABS.CA is down by 0%. In the past month the price decreased by -7.14%. In the past year, price decreased by -27.78%.
LABS.CA Key Statistics
- Market Cap
- 27.616M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
LABS.CA Stock Performance
LABS.CA Stock Chart
LABS.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LABS.CA. When comparing the yearly performance of all stocks, LABS.CA is a bad performer in the overall market: 89.42% of all stocks are doing better.
LABS.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LABS.CA. While LABS.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
LABS.CA Earnings
On March 30, 2026 LABS.CA reported an EPS of 0 and a revenue of 11.06M. The company missed EPS expectations (-145.1% surprise) and missed revenue expectations (-8.27% surprise).
LABS.CA Forecast & Estimates
For the next year, analysts expect an EPS growth of 54.1% and a revenue growth 13.37% for LABS.CA
LABS.CA Groups
Sector & Classification
LABS.CA Financial Highlights
Over the last trailing twelve months LABS.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 22.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.22% | ||
| ROE | -21.2% | ||
| Debt/Equity | 0.01 |
LABS.CA Ownership
LABS.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.23 | 2.772B | ||
| CRON | CRONOS GROUP INC | 39.18 | 1.338B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.066B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 5.17 | 904.914M | ||
| GUD | KNIGHT THERAPEUTICS INC | 155.29 | 730.324M | ||
| DHT-U | DRI HEALTHCARE TRUST | 5.33 | 671.122M | ||
| WEED | CANOPY GROWTH CORP | N/A | 565.768M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 22.49 | 475.264M | ||
| TSND | TERRASCEND CORP | N/A | 349.699M | ||
| HITI | HIGH TIDE INC | 10.35 | 283.038M | ||
| ACB | AURORA CANNABIS INC | 59.28 | 271.641M | ||
| OGI | ORGANIGRAM GLOBAL INC | 28.16 | 261.773M | ||
| CRDL | CARDIOL THERAPEUTICS INC-A | N/A | 221.245M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About LABS.CA
Company Profile
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
Company Info
IPO: 2018-02-09
MEDIPHARM LABS CORP
151 John Street
Barrie ONTARIO L4N 2L1 CA
CEO: Patrick McCutcheon
Employees: 161
Phone: 17057197425
MEDIPHARM LABS CORP / LABS.CA FAQ
What does MEDIPHARM LABS CORP do?
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 161 full-time employees. The company went IPO on 2018-02-09. The firm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. The company develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. The firm cultivates and processes cannabis to sell as dried flower, pre-roll and other cannabis products for adult use, medical, and international markets. The firm also provides GMP flower sourcing, packaging, and distribution services for select international clients. Its wholly owned subsidiary Harvest Medicine Inc. operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions. Its international subsidiaries include Beacon Medical Germany GmbH and Beacon Medical Australia Pty Ltd.
What is the current price of LABS stock?
The current stock price of LABS.CA is 0.065 CAD.
What is the dividend status of MEDIPHARM LABS CORP?
LABS.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of LABS stock?
LABS.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is MEDIPHARM LABS CORP (LABS.CA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LABS.CA.
What is the expected growth for LABS stock?
The Revenue of MEDIPHARM LABS CORP (LABS.CA) is expected to grow by 13.37% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of LABS stock?
MEDIPHARM LABS CORP (LABS.CA) has a market capitalization of 27.62M CAD. This makes LABS.CA a Nano Cap stock.